Tidemark LLC lessened its holdings in Immuneering Co. (NASDAQ:IMRX – Free Report) by 14.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,400 shares of the company’s stock after selling 7,450 shares during the quarter. Tidemark LLC owned 0.14% of Immuneering worth $98,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Separately, HighTower Advisors LLC grew its position in shares of Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock valued at $157,000 after acquiring an additional 18,000 shares during the period. 67.65% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on the company. Morgan Stanley downgraded Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price target on shares of Immuneering in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a report on Thursday, February 6th.
Immuneering Trading Up 3.9 %
Immuneering stock opened at $1.60 on Friday. The firm has a 50 day simple moving average of $1.84 and a 200 day simple moving average of $1.97. Immuneering Co. has a 1-year low of $1.00 and a 1-year high of $3.83. The firm has a market capitalization of $49.68 million, a price-to-earnings ratio of -0.81 and a beta of -0.32.
About Immuneering
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Read More
- Five stocks we like better than Immuneering
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividend Champions? How to Invest in the Champions
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is Put Option Volume?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding IMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immuneering Co. (NASDAQ:IMRX – Free Report).
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
